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The treatment of multiple myeloma has rapidly evolved
over the past 8 years. During this period we have seen the
introduction of two immunomodulatory drugs and a pro-
teasome inhibitor for the treatment of myeloma. Each of
these drugs has shown to be effective as single agent as
well as in combinations in relapsed and/or refractory
myeloma. And the optimum use of these drugs upfront,
both for transplant eligible as well as transplant ineligible
patients has been the focus of intense clinical investiga-
tions as reported by the investigators from US as well as
Europe in the last ASH meeting.
A series of large randomized trials have established the
addition of a novel agent, either thalidomide or borte-
zomib, to melphalan and prednisone as the standard of
care for transplant ineligible patients. With longer follow-
up for a median of 25.9 months VISTA trial showed con-
tinued survival benefit for patients randomized to receive
upfront bortezomib; three year OS was 72% for VMP
compared to 59% for MP. VMP improved outcome in all
patients, whether under or over age 75 years, with or with-
out modest renal impairment, as well a patient with
adverse prognostic features by cytogenetics or fish. These
improvements in outcome came with no difference in
hematologic toxicity or HZV infection, but higher inci-
dence of peripheral sensory neuropathy (grade  3 13%)
from bortezomib.
Addition of thalidomide to MP had been shown to
improve the progression-free and OS among transplant
ineligible patients. However, recent updates of 3 different
studies, Italian study (GIMEMA), the Dutch study
(HOVON 49) and the Scandinavian study showed
improvement in progression-free survival but not OS.
This may be related to differences in the dose intensity
and tolerability of the treatment, lack of efficacy of thalid-
omide in high-risk cytogenetic group and availability of
other novel agent to rescue upon relapse.
The addition of thalidomide to VMP regimen (VMPT) was
compared to VMP in a large randomized trial. In the pre-
liminary analysis after a short follow-up showed no
improvement in the PFS or OS but notable increase in tox-
icity for the four drug combination. The same study
showed that weekly administration of bortezomib was
well tolerated with much lower incidence of grade  3
peripheral neuropathy of 2% without significant loss of
efficacy.
Earlier reports on ECOG trial E4A03 comparing lenalido-
mide with low-dose or high-dose dexamethasone highly
favored low-dose dexamethasone arm for EFS and OS.
However, with longer follow-up (median 36 months) the
updated results of the trial showed identical 3-year sur-
vival outcome of 75%; but progression-free survival
favored low-dose dexamethasone arm. When land mark
analysis is performed at the end of four cycles, 3-year sur-
vival of patients who proceeded to transplant immedi-
ately (N = 90) was 92%; while those who stayed on the
primary therapy whether high-dose or low-dose dexame-
thasone, their 3-year survival was 79%. Thus, lenalido-
mide and dexamethasone is highly active in newly
from Current trends in leukemia, lymphoma and myeloma
White Plains, NY, USA. 31 January 2009
Published: 26 June 2009
Journal of Hematology & Oncology 2009, 2(Suppl 1):A4 doi:10.1186/1756-8722-2-S1-A4
<supplement> <title> <p>Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008</p> </title> <editor>Delong Liu</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1756-8722-2-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jhoonline.org/content/2/S1/A4
© 2009 Jagannath; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
Journal of Hematology & Oncology 2009, 2(Suppl 1):A4 http://www.jhoonline.org/content/2/S1/A4Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
diagnosed myeloma patients both as an induction ther-
apy pre-transplant for newly diagnosed myeloma as well
as primary therapy for patients ineligible for stem cell
transplantation.
Lenalidomide was unable to overcome the adverse prog-
nostic features identified by cytogenetics, FISH or labeling
index as noted by a single institutional study of 100
patients with lenalidomide and weekly dexamethasone.
Two large randomized trials have shown bortezomib
based induction therapies pretransplant improve the
response rate before and after stem cell transplantation
and with short follow-up there is improved progression-
free survival at 2 years. The first trial was performed by the
French investigators (IFM) which compared four cycles of
bortezomib and dexamethasone against four cycles of
VAD chemotherapy. At the end of induction therapy 39%
were in >VGPR after bortezomib-dexamethasone com-
pared to 16% after VAD (p < 0.0001). With a median fol-
low-up of 28 months the progression-free survival was
superior for the bortezomib and dexamethasone arm with
2 year PFS of 69% vs. 60% for the VAD arm (p0.011).
The second trial was reported by the Italian group which
compared 3 cycles of thalidomide and dexamethasone
(TD) to the same regimen with added bortezomib (VTD).
Again, the addition of bortezomib to thalidomide and
dexamethasone significantly improved the response rates
pretransplant; VGPR or better was 62% for VTD compared
to 29% for TD. With a short median follow-up time of 15
months the projected two-year PFS was 90% for VTD arm
compared to 80% for TD arm (p = 0.009). Other studies
have shown replacing the vincristine in the VAD regimen
with either thalidomide (TAD) or bortezomib (PAD) also
improves the response rate and progression-free survival
after transplantation.
In conclusion, advent of novel agents has substantially
improved the outcome of patients with newly diagnosed
myeloma. MP plus thalidomide or bortezomib should be
the choice of therapy for transplant ineligible patients.
Brief induction with bortezomib containing regimen is
the treatment of choice for transplant eligible patients.
Lenalidomide and low-dose dexamethasone is an excel-
lent treatment option for both transplant eligible as well
as ineligible patients. Bortezomib has been shown clearly
to improve the outcome of patients with high-risk genetic
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